In classical hodgkin's lymphoma patients with a postive PET after 2 cycles, are you routinely transitioning to escalated BEACOPP?  

Does the more recent data regarding the continued utility of brentuximab vedotin and the utility of PD-1 inhibitors factor in to your reasoning at all? 



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Norton Cancer Institute
Thank you for this thoughtful answer. The long ter...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice